The current status of platelet suppressive drugs in the treatment of thrombosis.
D000368:Aged; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects*; D006328:Cardiac Catheterization / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000188:drug therapy; D011183:Postoperative Complications / Q000188:drug therapy; D006435:Renal Dialysis / Q000009:adverse effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013922:Thrombocytosis / Q000188:drug therapy; D013923:Thromboembolism / Q000188:drug therapy*
D006886:Hydroxychloroquine; D004176:Dipyridamole; D002994:Clofibrate; D001241:Aspirin; D013442:Sulfinpyrazone